Emcure Pharmaceuticals Ltd - Company Profile
Powered by 
All the sales intelligence you need on Emcure Pharmaceuticals Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Emcure Pharmaceuticals Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Emcure Pharmaceuticals Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View up-to-date information on Emcure Pharmaceuticals Ltd patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| CA3044636C | Grant | Lipid formulations of carmustine | A61K31/175; A61K9/127; A61K9/1277; A61K9/19; A61K9/5123 | October 03, 2023 |
| EP4007599A4 | Search Report | Ophthalmische zusammensetzung von bevacizumab | A61K39/39591; A61K47/02; A61K47/26; A61K9/0048; A61M5/002; C07K1/36; C07K16/065; C07K16/22; C07K2317/14; C07K2317/24; C07K2317/76 | July 26, 2023 |
| US20230210793A1 | Application | Method for rapid infusion of carmustine | A61K31/17; A61K31/175; A61K31/198; A61K31/7048; A61K31/7068; A61K45/06; A61K47/02; A61K47/10; A61K47/26; A61K9/0019; A61K9/08 | July 06, 2023 |
| CA3057479C | Grant | Improved kit for preparing injectable carmustine solutions | A61J1/1443; A61J1/2096; A61K31/17; A61K31/175; A61K47/02; A61K47/10; A61K47/26; A61K9/0019; A61K9/08; A61K9/19; A61P35/00 | July 04, 2023 |
| US20230135144A1 | Application | Stable ready-to-use carmustine pharmaceutical composition | A61K31/175; A61K47/26; A61K9/0019; A61K9/0029; A61K9/08 | May 04, 2023 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer